Increase/Decrease in Cash: The total change in cash for the company over the given period.
Inhibikase Therapeutics, Inc. (IKT) had Increase/Decrease in Cash of $82.73M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-12.73M |
|
-- |
|
-- |
|
$13.78M |
|
$-13.78M |
|
$1.04M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-13.78M |
|
$-13.78M |
|
98.31M |
|
98.31M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$180.11M |
|
-- |
|
$1.10M |
|
$181.20M |
|
$8.30M |
|
-- |
|
-- |
|
$8.30M |
|
$172.90M |
|
$172.90M |
|
$172.90M |
|
131.69M |
|
| Cash Flow Statement Financials | |
$-27.79M |
|
$2.05M |
|
$108.46M |
|
$56.49M |
|
$139.22M |
|
|
Increase/Decrease in Cash |
$82.73M |
$15.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-27.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-7.37% |
|
-7.37% |
|
-7.03% |
|
-7.37% |
|
$1.31 |
|
$-0.28 |
|
$-0.28 |
|